Challenges in the Development of Novel Cardiovascular Therapies
Authors:
- 23 June 2017
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 102 (2) , 194-196
Abstract
Cardiovascular disease accounts for nearly one in three deaths globally, but few novel therapies have reached patients and clinicians in recent years. This translational report reviews trends in the development and approval of cardiovascular drugs and evaluates recent innovation in the field of cardiovascular disease therapeutics. New policies are needed to better support the development of safe and effective therapies with the greatest potential to improve patient health outcomes.Keywords
This publication has 4 references indexed in Scilit:
- Cardiovascular Drug DevelopmentJACC, 2015
- The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative DrugsHealth Affairs, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Varespladib and Cardiovascular Events in Patients With an Acute Coronary SyndromeJAMA, 2014